Previous 10 | Next 10 |
Peer Reviewed Results from PROPEL Show Treatment with AT-GAA Provided Clinically Meaningful Improvements Over Standard of Care, including ERT Experienced Patients with High Unmet Need AT-GAA Deemed to Provide a Differentiated Mechanism of Action and Potential Alternative Treatme...
We are circling back to Amicus Therapeutics today for the first time since this spring. The stock is trading near a longer-term floor, the company is moving toward profitability and has potential catalysts on the horizon. A full investment analysis is provided in the paragraphs be...
PHILADELPHIA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 8:00 a.m. E.T. A l...
Image source: The Motley Fool. Amicus Therapeutics, inc (NASDAQ: FOLD) Q3 2021 Earnings Call Nov 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Amicus Therapeutics, inc (FOLD) Q3 2021 Earnings Call Transcript
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Amicus Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
Amicus Therapeutics, Inc. (FOLD) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Participants Andrew Faughnan – Head-Investor Relations John Crowley – Chairman and Chief Executive Officer Bradley Campbell – President and Chief Operating Officer Jeff C...
Amicus Therapeutics (NASDAQ:FOLD): Q3 GAAP EPS of -$0.19 misses by $0.02. Revenue of $79.54M (+17.9% Y/Y) misses by $0.79M. Press Release Cash, cash equivalents, and marketable securities totaled $557.0 million at September 30, 2021, compared to $483.3 million at December 31, 2020 For furth...
3Q21 Total Galafold ® Revenue of $79.5M – an 18% increase over 3Q20 Reiterating 2021 Revenue Guidance of $300M-$315M AT-GAA BLA and NDA for Pompe Disease Accepted for Review by the U.S. FDA; Marketing Authorization ...
Amicus Therapeutics (NASDAQ:FOLD) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.18 and the consensus Revenue Estimate is $80.33M (+19.1% Y/Y). Over the last 1 year, FOLD has beaten EPS estimates 25% of the time and...
ADT,AGEN,AGTC,ALLT,APRN,AUD,OTCPK:BAYZF,BHVN,BNTX,BSY,CAH,CANO,CCO,CEVA,CNCE,CORR,DCTH,DHI,DRNA,EBIX,ECOM,EGRX,EPZM,EXK,FOLD,GILT,GLNG,GOL,HAE,HAIN,HGV,HUYA,IGT,IIVI,INSW,ISEE,ITCI,KNDI,KPLT,MIDD,MLCO,MNTV,MRNS,MRSN,MSGE,OTCPK:NSANY,NSPR,NUWE,OCGN,OESX,OSG,OWL,PLTR,PRPL,PRTY,QTNT,SATS,SEAS,SE...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 8, 2024, at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2024. Par...
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...